Azienda Ospedaliera Ordine Mauriziano di Torino Ospedale Umberto I , SCDU Oncologia
Welcome,         Profile    Billing    Logout  
 15 Trials 
7 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Maio, Massimo Di
BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Recruiting
2
16
Europe
Cetuximab, Encorafenib
Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories
Colorectal Cancer
08/26
04/27
GDFather-NEO, NCT06059547 / 2022-002816-22: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting
2
30
Europe
Nivolumab, Visugromab (CTL-002), Placebo
CatalYm GmbH, CatalYm GmbH
Bladder Cancer, Adult Solid Tumor
08/25
09/26
NCT05630937 / 2020-001002-26: Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

Terminated
1/2
31
Europe, US
NMS-01940153E
Nerviano Medical Sciences
Unresectable Hepatocellular Carcinoma (HCC)
01/24
08/24
Maruzzo, Marco
TIDE-A, NCT04698213: Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

Recruiting
2
75
Europe
Axitinib Oral Tablet, Avelumab
Consorzio Oncotech, Clinical Research Technology S.r.l.
Renal Carcinoma Metastatic
09/23
10/24
GDFather-NEO, NCT06059547 / 2022-002816-22: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting
2
30
Europe
Nivolumab, Visugromab (CTL-002), Placebo
CatalYm GmbH, CatalYm GmbH
Bladder Cancer, Adult Solid Tumor
08/25
09/26
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
06/25
07/26
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting
1
51
Europe, US
UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine
UroGen Pharma Ltd.
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
12/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Maio, Massimo Di
BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC

Recruiting
2
16
Europe
Cetuximab, Encorafenib
Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories
Colorectal Cancer
08/26
04/27
GDFather-NEO, NCT06059547 / 2022-002816-22: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting
2
30
Europe
Nivolumab, Visugromab (CTL-002), Placebo
CatalYm GmbH, CatalYm GmbH
Bladder Cancer, Adult Solid Tumor
08/25
09/26
NCT05630937 / 2020-001002-26: Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy

Terminated
1/2
31
Europe, US
NMS-01940153E
Nerviano Medical Sciences
Unresectable Hepatocellular Carcinoma (HCC)
01/24
08/24
Maruzzo, Marco
TIDE-A, NCT04698213: Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

Recruiting
2
75
Europe
Axitinib Oral Tablet, Avelumab
Consorzio Oncotech, Clinical Research Technology S.r.l.
Renal Carcinoma Metastatic
09/23
10/24
GDFather-NEO, NCT06059547 / 2022-002816-22: Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

Active, not recruiting
2
30
Europe
Nivolumab, Visugromab (CTL-002), Placebo
CatalYm GmbH, CatalYm GmbH
Bladder Cancer, Adult Solid Tumor
08/25
09/26
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
06/25
07/26
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting
1
51
Europe, US
UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine
UroGen Pharma Ltd.
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
12/25
12/25

Download Options